Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Intermediate uveitis

8,403 views

Published on

presentation

Published in: Health & Medicine
  • Login to see the comments

Intermediate uveitis

  1. 1. INTERMEDIATE UVEITIS PRESENTER- DR BARUN GARG MODERATOR- DR HIMANTO HAZARIKA RIO, GUWAHATI
  2. 2. ANATOMY
  3. 3. • Pars plana is a flat extension from posterior aspect of ciliary processes to ora serrata • 3.5 to 4 mm in length • Around 3 mm from limbus- ciliary processes
  4. 4. INTRODUCTION Inflammation of uveal tract – UVEITIS ANATOMICAL CLASSIFIACTION A)ANTERIOR- iritis, anterior cyclitis, iridocyclitis B)INTERMEDIATE C)POSTERIOR- choroiditis, chorioretinitis, retinochoroiditis, neuroretinitis D)PANUVEITIS
  5. 5. International Uveitis Study Group (IUSG) Anatomic Classification of Uveitis* Anterior uveitis Primary site of inflammation: anterior chamber Intermediate uveitis Primary site of inflammation: vitreous Posterior uveitis Primary site of inflammation: retina or choroid Panuveitis Primary site of inflammation: anterior chamber, vitreous, retina or choroid
  6. 6. INTERMEDIATE UVEITIS • Intermediate uveitis (IU) is described as inflammation in the anterior vitreous, pars plana and the peripheral retina • The diagnostic term pars planitis should be used only for that subset of IU where there is snow bank or snowball formation occurring in the absence of an associated infection or systemic disease
  7. 7. DEMOGRAPHY OF INTERMEDIATE UVEITIS • Incidence in population – 1 in 15000 • % of IU in cases of uveitis- 8 to 22% • Incidence in indian referral eye hospital- 19.8% • Male: female- 54:46 • Average age in various studies- 23 to 28 years • Bilateral- 70 to 90% at presentation
  8. 8. • The IUSG (International Uveitis Study Group) suggested the term IU to denote an idiopathic inflammatory syndrome, mainly involving the anterior vitreous, peripheral retina and the ciliary body with minimal or no anterior segment or chorioretinal sign
  9. 9. • IU is not hereditary though it has been observed in families. • patients who are HLA-DR15-positive and have IU may have systemic findings of another HLA- DR15-related disorder- multiple sclerosis, optic neuritis, and narcolepsy
  10. 10. ETIOPATHOGENESIS • Exact theory yet to be known • may be initiated by an unknown antigen, leading to a clinical picture of vasculitis and vitreous cells. • antigen may be infectious(Lyme's, syphilis and cat-scratch fever) , autoimmune-(multiple sclerosis and sarcoidosis) • Type II collagen in the vitreous may be an autoantigen in some patients contd...
  11. 11. • Intermediate uveitis seems to be a T-cell- mediated disease • Lymphocytic infiltration of the retinal venules leads to the clinical picture of vasculitis. • T-cells are the predominant cell type in the vitreous up to 95% of all cells, of which CD4+ cells are 35-90%. • Macrophages -second most important cells • In active inflammation epitheloid cells and multinucleated giant cells are seen • HLA associations include HLA-DR, B8, and B51, the most significant being HLA-DR which occurs in 67-72% of patients
  12. 12. HISTO-PATHOLOGY • Histological studies of the peripheral retina and ciliary body demonstrate – condensed vitreous, fibroblasts, spindle cells, lymphocytes and blood vessels and prominent lymphocyte cuffing of retinal veins. • Pars plana exudates appear to consist of loose fibrovascular layer containing scattered mononuclear inflammatory cells and a few fibrocyte-like cells adjacent to the hyperplastic nonpigmented epithelium of the pars plana.
  13. 13. CLINICAL FEATURES One of the most under diagnosed uveitic disease- lack of routine examination of pars plana, lack of awareness SYMPTOMS-(initially) • floaters • Mild blurring of vision • Mild photophobia • Uncommon- pain, redness
  14. 14. SIGNS- • Conjunctiva- mild congestion • Anterior chamber- no or minimal findings • Cells and flare, KPs, posterior synechiae ( usually inferiorly) • Vitritis is a characteristic feature of IU, and it is typically described as vitreous haze ranging from trace to 4+
  15. 15. FUNDOSCOPY- • Characteristic mobile, globular, yellow-white "snowballs" ("ants' eggs") seen in the inferior peripheral vitreous. • They lie close to the retina, but are not in contact with it. • Inflammatory exudates accumulate over pars plana to form SNOWBANK • Periphlebitis of peripheral veins in vicinity of exudates
  16. 16. CONTD.... • Later the vitreous shows degenerative changes with fibre-like cylindrical condensations of coarse vitreous strands. • Posterior vitreous detachment (PVD) is common • Retinal changes in IU include tortuosity in arterioles and venules, sheathing of peripheral veins, neovascularizations and retinal detachments • Cystoid macular edema
  17. 17. The hallmark of pars planitis are • the white or yellowish-white pars plana exudates ("posterior hypopyon") and • collagen band (snowbank) over the pars plana. • These exudates are preretinal, peripheral, typically inferior but may also be superior or divided into multiple foci or extend 360 degrees over the entire pars plana
  18. 18. DIFFERNTIAL DIAGNOSIS
  19. 19. Contd... MOST COMMON- • Idiopathic • Syphilis • Lyme disease • Multiple sclerosis • Sarcoidosis • Bartonella LESS COMMON- • Lymphoma • HTLV • Toxocara • behcets
  20. 20. • TABLE 1295
  21. 21. Multiple sclerosis: About 3-27% of patients develop pars planitis and 7.8-14.8% of patients with IU/pars planitis develop MS. • characterized by pars plana snowbanks, retinal periphlebitis (in 5-20%) and panuveitis are the commonest manifestations of MS and up to 95% are bilateral Intraocular lymphoma:10-20% the disease commences as vitreous or retinal infiltrates mimicking uveitis and 95% are non-Hodgkins B-cell lymphomas
  22. 22. Sarcoidosis: About 23-26% of patients with sarcoidosis develop IU • typical ocular findings-CME, optic disc swelling, periphlebitis, and retrobulbar optic neuritis were seen in patients with IU, both with or without sarcoidosis • It is commonly bilateral, and presents as IU and granulomatous anterior uveitis
  23. 23. Syphilis: uveitis is the commonest presentation of syphilis. • Anterior uveitis( granulomatous and nongranulomatous), posterior uveitis, panuveitis, vitritis, vasculitis, retinitis, placoid choroiretinitis and optic nerve involvement are also seen in eyes with syphilitic uveitis. • IU has been described to occur in Lyme's disease caused by another spirocheate- Borrelia burgdorferi, both in adults and in children
  24. 24. DIAGNOSIS • Diagnosis is based on clinical findings • patient's history should focus-duration of symptoms, the number of recurrences, and findings that might be associated with systemic disorders
  25. 25. Ancillary test- FFA- detection of CME - capillary and disc hyperflourescence, staining of vessel wall, fern pattern radial hyperflourescence
  26. 26. • USG- exudates over pars plana • ERG- abnormal b wave implicit time • UBM- exudates and vitritis
  27. 27. LAB INVESTIGATIONS • Baseline invs- CBC, ESR, RFT,LFT, • PPD test - exclude tuberculosis/sarcoidosis • Chest X-ray-- findings indicative of sarcoidosis or tuberculosis. • Sarcoidosis – CT scan lungs, ACE enzymes • Serologic testing for- cat-scratch disease, syphilis (VDRL, FTA-ABS)and Lyme's • HLA DR2 typing • Vitreous tap
  28. 28. COMPLICATIONS 1)CME- Upto 50% patients Most common cause of visual loss Prevalance increases with severity of inflammation Epiretinal membrane
  29. 29. CATARACTS- • Either due to inflammation or steroids • Most often type – PSC • 15-50% of eyes • GLAUCOMA
  30. 30. • Optic disc edema- due to intraocular inflammation 20% patients • optic neuritis – may or may not be associated with multiple sclerosis • NVD/NVE
  31. 31. • Venous sheathing- most often benign • VASCULITIS- associated with ischaemia Sheathing +/- • Retinal detachment A) Serous RD B) Rhegmatogenous RD- associated with dialysis at snow bank
  32. 32. TREATMENT Four step approach by Kaplan Step 1- • Posterior sub tenon injection of steroids- methyl prednisolone 40mg or triamcinolone 40 mg (0.75 to 1 ml) • Preferably in upper temporal quadrant • 2 to 3 injections at interval of 3-4 weeks- resolution • Topical 1% prednisolone acetate • Systemic steroids 1mg/kg can be added (mantoux test to be done) • Improvement in vision 67% cases • Appropriate antibiotics for infections causes Compliactions- rise in iop, ptosis, globe perforation, necrotising scleritis
  33. 33. Step 2- • Not responded to peri ocular/ systemic steroids • Cryopexy can be done • Mechanism- destruction of hyperemic vascular component of diseases by eliminating neovasclar and ischaemic tissue • Double freeze and thaw technique • Impovement in vision- 32 to 67 percent • Complications- RD, PVR • Doesnt prevent recurrence • Indirect laser also used
  34. 34. Step 3- • Not responding to cryopexy also • Pars plana vitrectomy is done • Helps in early resolution of CME Step 4- • If step 1 fails- immunosuppresive agents can be used • Cyclophosphamide, azathioprine, chlorambucil • Azathioprine- 50 mg thrice daily for four months(tapered) • Platelet counts, WBC regularly monitored
  35. 35. Current guidelines in many institutes
  36. 36. • Some advocate use of a combination of betamethasone and depot methylprednisolone(sub tenon) in an effort to achieve early onset and prolonged duration of action. • Intravitreal triamcinolone acetonide injections have been used to treat CME • use of somatostatin analogues (Octreotide) IM and intravitreal bevacizumab (Avastin) in patients with refractory uveitic CME. • the surgical implantation of a fluocinolone acetonide (Retisert) or dexamethasone (Ozurdex) implant can be considered
  37. 37. STEROID REFRACTORY UVEITIS • Cyclosporine, tacrolimus, azathioprine, and methotrexate are the most commonly used agents with documented efficacy in many uveitic conditions • Chlorambucil can be considered for intractable cases NEWER DRUGS USED- • infliximab, (anti-TNF) monoclonal antibody, has been shown to be effective in improving macular thickness and visual acuity in patients with uveitic refractory CME due to intermediate uveitis or other noninfectious uveitis. • Daclizumab, an interleukin-2 receptor blocking antibody, has been shown to be effective in noninfectious uveitis in a multicenter nonrandomized interventional case series • interferon-beta (INF-beta), which has an established value in the treatment of MS, appears to have a positive effect in terms of visual acuity, CME
  38. 38. • MANAGEMENT OF GLAUCOMA • Rx OF CATARACT • Anti VEGF for neovascularisation • Supportive rx

×